trial

Pharmacokinetic Study of MIN-101 in Healthy Subjects

NCTId NCT02232529
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 32 (actual)
Sponsored by Minerva Neurosciences
Primary completion 2015-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
—
Start
2014-09
Primary completion
2015-02
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Roluperidone

Sponsors

Minerva NeurosciencesLead Sponsor

Investigators

1
Pui Leung, M.DPrincipal Investigator

Sites

1 total
Ruddington, Nottingham, United Kingdom

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE1
Primary Completion Date
2015-02
Status
COMPLETED
relationships
The graph out of here
drug
Roluperidone
drug
lead_sponsor
Minerva Neurosciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Pui Leung, M.D
person